Roeland George Willehad Verhaak was born in Wijchen, the Netherlands, on September 29 1976. After fi nishing his VWO education at the Kottenpark College in Enschede in 1996, he started a curriculum Biomedical Health Sciences at the Catholic University Nijmegen (KUN, currently Radboud University). As part of this education, he followed majors in pathobiology and toxicology, and a minor in computer science. A toxicology internship, titled ‘Mitochondrial toxicity of nuclease reverse transcriptase inhibitors, was completed at the Department of Pharmacology and Toxicology of the KUN under supervision of Dr. Roos Masereeuw. A second intership project, ‘Development of a diagnostic marker of multiple sclerosis’, was completed at the Department of Biochemistry, under supervision of Dr. Rinie van Boekel en Prof.dr. W. Van Venrooij. He obtained his Masters–degree in August 2000. After having started a project at the Department of Medical Informatics of the KUN in October 2000 in which he worked on structuring of temporal data, he switched to the bioinformatics company Dalicon BV in April 2002. At Dalicon, he worked as software engineer, with a particular focus at the database system SRS. In April 2003 he started a PhD-project at the Department of Hematology at the Erasmus MC in the lab of Prof.dr. Bob Löwenberg, supervised by Dr. Peter Valk. This work has been described in this thesis. From March 2006 until June 2006, he was a visiting scientist of the Department of Biostatistics and Computational Biology of the Dana-Farber Cancer Institute in Boston, supervised by Prof.dr. John Quackenbush. The author wil continue his academic career at the Broad Institute in Boston, a research collaboration of MIT, Harvard and its affiliated hospitals, and the Whitehead Institute.

Dutch Cancer Society (Koningin Wilhelmina Fonds), Löwenberg, Prof. Dr. B. (promotor)
B. Löwenberg (Bob)
Erasmus University Rotterdam
hdl.handle.net/1765/8124
Erasmus MC: University Medical Center Rotterdam

Verhaak, R. (2006, November 24). Gene expression profi ling of acute myeloid leukemia. Retrieved from http://hdl.handle.net/1765/8124